Literature DB >> 30819552

Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease.

Fabien Picard, Deepak L Bhatt, Grégory Ducrocq, Yedid Elbez, Roberto Ferrari, Ian Ford, Jean-Claude Tardif, Michal Tendera, Kim M Fox, Philippe Gabriel Steg.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30819552     DOI： 10.1016/j.jacc.2019.01.016

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  10 in total

Review 1.  Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.

Authors:  Fabien Picard; Philippe Gabriel Steg
Journal:  Curr Atheroscler Rep       Date:  2021-03-31       Impact factor: 5.113

2.  The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl.

Authors:  Catherine G Derington; Adam P Bress; Jennifer S Herrick; Wenjun Fan; Nathan D Wong; Katherine E Andrade; Jonathan Johnson; Sephy Philip; David Abrahamson; Lixia Jiao; Deepak L Bhatt; William S Weintraub
Journal:  Am J Prev Cardiol       Date:  2022-04-28

Review 3.  Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.

Authors:  William E Boden; Deepak L Bhatt; Peter P Toth; Kausik K Ray; M John Chapman; Thomas F Lüscher
Journal:  Eur Heart J       Date:  2020-06-21       Impact factor: 29.983

4.  REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.

Authors:  Deepak L Bhatt; Michael Miller; Eliot A Brinton; Terry A Jacobson; Ph Gabriel Steg; Steven B Ketchum; Ralph T Doyle; Rebecca A Juliano; Lixia Jiao; Craig Granowitz; Jean-Claude Tardif; Brian Olshansky; Mina K Chung; C Michael Gibson; Robert P Giugliano; Matthew J Budoff; Christie M Ballantyne
Journal:  Circulation       Date:  2019-11-11       Impact factor: 29.690

5.  Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?

Authors:  Jean Ferrières; Vincent Bataille; Etienne Puymirat; François Schiele; Tabassome Simon; Nicolas Danchin
Journal:  Clin Cardiol       Date:  2020-07-28       Impact factor: 2.882

6.  Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study.

Authors:  Andrew P Ambrosy; Jingrong Yang; Sue Hee Sung; Amanda R Allen; Jesse K Fitzpatrick; Jamal S Rana; Jeffrey Wagner; Sephy Philip; David Abrahamson; Craig Granowitz; Alan S Go
Journal:  J Am Heart Assoc       Date:  2021-10-08       Impact factor: 5.501

Review 7.  Egyptian practical guidance in hypertriglyceridemia management 2021.

Authors:  Hesham Salah El Din Taha; Hossam Kandil; Nabil Farag; Abbas Oraby; Magdy El Sharkawy; Fouad Fawzy; Hossam Mahrous; Juliette Bahgat; Mina Samy; Mohamed Aboul; Mostafa Abdrabou; Mirna Mamdouh Shaker
Journal:  Egypt Heart J       Date:  2021-12-20

8.  Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.

Authors:  Benjamin E Peterson; Deepak L Bhatt; Ph Gabriel Steg; Michael Miller; Eliot A Brinton; Terry A Jacobson; Steven B Ketchum; Rebecca A Juliano; Lixia Jiao; Ralph T Doyle; Craig Granowitz; C Michael Gibson; Duane Pinto; Robert P Giugliano; Matthew J Budoff; Jean-Claude Tardif; Subodh Verma; Christie M Ballantyne
Journal:  J Am Heart Assoc       Date:  2022-03-09       Impact factor: 6.106

9.  Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.

Authors:  R Preston Mason; Peter Libby; Deepak L Bhatt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-03-26       Impact factor: 8.311

Review 10.  The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction.

Authors:  Xiaowen Wang; Subodh Verma; R Preston Mason; Deepak L Bhatt
Journal:  Curr Diab Rep       Date:  2020-10-23       Impact factor: 4.810
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.